NICE set the UK SMA access sequence before any new entrant arrives: gene therapy claimed the pre-symptomatic subgroup through HST15 and HST24, and TA1162 then moved nusinersen and risdiplam to routine funding for the populations gene therapy does not reach.
NICE recommended onasemnogene abeparvovec (Zolgensma) for symptomatic type 1 SMA in July 2021 under HST15, through its Highly Specialised Technologies route and a managed access agreement. In April 2023, HST24 partially updated that guidance and extended the recommendation to pre-symptomatic 5q SMA with up to 3 SMN2 copies in babies aged 12 months and under. The pre-symptomatic subgroup matters commercially because NICE's own modelling treats an infant treated before symptom onset as gaining more QALYs from a single durable dose than a symptomatic infant, which is what carried the value case for a one-time therapy priced at a £1,795,000 list price before its confidential discount. The evidence base HST24 relied on was the single-arm SPR1NT trial in 29 babies, so the durability of that QALY gain remains the open question a second gene therapy would have to answer.
For every SMA patient outside that gene therapy window, NICE finalised TA1162 in 2026, moving nusinersen (Spinraza) and risdiplam (Evrysdi) from the time-limited managed access schemes that had run since 2019 to routine NHS funding. TA1162 did not simply confirm the two chronic agents; it positioned them for patients who have not responded to or are unsuitable for onasemnogene, formalising a sequence in which gene therapy is the first-line economic choice and chronic therapy follows it. A new UK entrant therefore does not face an open field. It inherits a defined subgroup hierarchy, with the pre-symptomatic identified population anchored to a one-time durability argument and the symptomatic and post-gene-therapy populations anchored to two routinely-funded chronic comparators. The strategic question is which of those populations a new agent can still claim, and what comparator and evidence NICE will demand there.
UK SMA NICE appraisal precedent — a sequenced pathway, not an open field
| Agent (Brand / INN) | NICE Appraisal | Population Recommended | NHS Access Status | Comparator Implication for a New Entrant |
|---|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | HST15 (2021); HST24 (2023) | Symptomatic type 1 (HST15); pre-symptomatic, up to 3 SMN2 copies (HST24) | Commissioned under managed access via the Highly Specialised Technologies route | One-time gene therapy holds the pre-symptomatic subgroup on a durability argument |
| Spinraza (nusinersen) | TA588 (2019), superseded by TA1162 (2026) | 5q SMA, pre-symptomatic and types 1 to 3 | Routine NHS funding under TA1162 | Routinely-funded chronic comparator for symptomatic and post-gene-therapy patients |
| Evrysdi (risdiplam) | TA755 (2021), superseded by TA1162 (2026) | 5q SMA types 1 to 3 and pre-symptomatic, 1 to 4 SMN2 copies | Routine NHS funding under TA1162 | Second routinely-funded chronic comparator; oral administration |
| New entrant | None | To be defined | To be established | Must claim a population and comparator not already closed by the sequence above |
Sources: NICE HST15 (onasemnogene abeparvovec, 2021) and HST24 (pre-symptomatic, 2023); NICE TA588 (nusinersen, 2019) and TA755 (risdiplam, 2021), both superseded by NICE TA1162 (nusinersen and risdiplam, 2026, review GID-TA11386 / ID6195).
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The verified subgroup hierarchy across pre-symptomatic, symptomatic type 1, types 2 to 3, and post-gene-therapy patients
- the comparator NICE will expect in each
- where a new agent has a defensible population to target
Delivers
- The durability and long-term-QALY gaps behind the HST24 value case
- how the value-dossier self-assessment tests a new durable therapy against them before submission
Delivers
- How routine funding of two chronic comparators resets the comparator defence
- why parity pricing against a routinely-funded incumbent will not clear NICE
- the levers a new chronic submission has left
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the SMA population a new agent can claim, not its price, is the first thing a submission must resolve
- The subgroup hierarchy NICE has already fixed through HST15, HST24 and TA1162, pressure-tested before the rest of the model is built
- NICE's two SMA routes: the Highly Specialised Technologies route for gene therapy (HST15, HST24) and the standard technology appraisal route for chronic therapy (TA588, TA755, TA1162)
- Why route selection sets the evidence bar, the QALY treatment and the modelling horizon a submission will face
- Population, Intervention, Comparator and Outcomes built around the verified subgroup split: pre-symptomatic with up to 3 SMN2 copies, symptomatic type 1, types 2 to 3, and post-gene-therapy patients
- Defining a target population that is not already closed by an existing NICE recommendation
- The 3-test comparator defence applied where the comparator shifts by population: one-time gene therapy in the pre-symptomatic subgroup, nusinersen or risdiplam in the symptomatic and post-gene-therapy populations
- Why parity pricing against a routinely-funded chronic comparator will not clear NICE after TA1162
- 5-module, 15-check self-assessment against submission readiness
- Testing a durable-therapy value case against the single-arm SPR1NT evidence and durability assumption behind HST24
- Durability, long-term-QALY and subgroup-identification gaps scored separately by likelihood of being raised and impact if raised
- Submission-blocking versus manageable classification for a gene therapy versus a chronic agent
- Economic model type selection and the one-time versus annual cost inputs, anchored on the £1,795,000 gene therapy list price and chronic-therapy annual costs
- Milestone timeline including the pre-symptomatic identification dependency the newborn-screening subgroup relies on
- The open HEOR, subgroup and comparator questions your team must close before the dossier is finalised
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx HTA strategy model is built from primary HTA-body sources: NICE technology appraisals, highly specialised technology evaluations, and final guidance documents, not secondary summaries. Every regulatory identifier is verified against the live NICE guidance page for the exact drug and indication before it is used, and every comparator claim is pressure-tested through the 3-test defence framework before being accepted.
UK spinal muscular atrophy HTA sources: NICE HST15 (onasemnogene abeparvovec, symptomatic type 1, 2021), HST24 (onasemnogene abeparvovec, pre-symptomatic, 2023), TA588 (nusinersen, 2019) and TA755 (risdiplam, 2021), both now superseded by TA1162 (nusinersen and risdiplam, 2026).
- HST15 recommendation for symptomatic type 1 SMA and HST24 extension to pre-symptomatic infants with up to 3 SMN2 copies verified against the live NICE Highly Specialised Technologies guidance pages
- TA588 (nusinersen) and TA755 (risdiplam) verified against live NICE guidance, including their supersession by TA1162 and its 2026 move to routine NHS funding
- Onasemnogene abeparvovec £1,795,000 list price and the chronic-therapy annual cost anchors verified against NICE guidance and NHS England SMA commissioning references
Frequently asked questions
Commission this model
AXLRx delivers rare-disease HTA strategy models built for market access and HEOR teams navigating an already-sequenced NICE access pathway. Custom model in 72 hours.
Specify your indication, target SMA population, HTA route, and comparator scope.
AXLRx analyst confirms subgroup target, comparator set, and evidence scope before building.
Research-verified HTA strategy model in 72 hours with optional analyst readout.